摘要
目的:研究绿原酸对移植性肿瘤的影响及与阿霉素联合用药后是否具有增敏作用。方法:建立H22肝癌、Lewis肺癌移植瘤模型,考察绿原酸对移植瘤的抑制作用及与阿霉素联合用药后对阿霉素抗肿瘤作用是否有增敏作用。结果:与模型组比较,绿原酸对H22肝癌、Lewis肺癌移植瘤有明显的抑制作用,剂量20mg/kg的抑制作用最强;与阿霉素联合用药后对肿瘤的抑制作用有一定增强趋势,但与单用阿霉素比较无显著性差异。结论:绿原酸可显著对抗H22肝癌、Lewis肺癌移植瘤的生长,但与阿霉素联合用药对其肿瘤的抑制作用无增敏性。
Objective： To study the effects of chlorogenic acid on transplantable tumor and its synergism when combinated with adriamycin. Method： Observe the inhibitory effect of ehlorogenic acid on tumor models about H22 hepatoma and Lewis lung cancer, and its synergism on the antitumor effects of adriamycin when combination. Results： compared with control, chlorogenic acid can significantly inhibit H22 hepatoma and Lewis lung cancer, and the dosage 20mg/kg showed the best effects. Though inhibitory effect was tendency progress in combination group, there were no statistic defferenee compared with adriamyein. Conclusion： Chlorogenic acid can prevent the transplantable tumor progress of H22 hepatoma and Lewis lung cancer when combinated with adriamycin, yet no synergism.
出处
《中药药理与临床》
CAS
CSCD
北大核心
2009年第2期43-45,共3页
Pharmacology and Clinics of Chinese Materia Medica
